Evogene Ltd. filed a Form D with the Securities and Exchange Commission on 2026-02-19.
Evogene Ltd. filed a Form D notice of an exempt securities offering with the SEC on February 19, 2026. The filing reports $3.38M sold. Its industry group is Pharmaceuticals. It names Ofer Haviv (President and Chief Executive Officer and Director), Yaron Eldad (Chief Financial Officer), Gabi Tarcic (Vice President Product) (SEC Form D, February 19, 2026).
Sell to companies like Evogene Ltd? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-02-19 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Evogene Ltd.
Free to see. No signup.
More on the people and the money behind Evogene Ltd., from the filings we hold.
Pharmaceuticals raises filed within 90 days of this one, largest first.
Get an email when Evogene Ltd. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Evogene Ltd. raises, hires or launches. No email unless you switch it on.
Watch Evogene Ltd. →Get the full cited report on Evogene Ltd.
What the filing shows about Evogene Ltd.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Evogene Ltd.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for Evogene Ltd. →
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 157 filings in Pharmaceuticals, totalled by week. The dot is this raise, $3.38M, on the same scale — one filing against the whole group's total, so it sits low by construction.
On the filing as: Executive Officer, Director.
Ofer Haviv is named as President and Chief Executive Officer and Director on the Form D that Evogene Ltd. filed with the SEC on 19 February 2026, one of 9 people that filing names.
On the filing as: Executive Officer.
Yaron Eldad is named as Chief Financial Officer on the Form D that Evogene Ltd. filed with the SEC on 19 February 2026, one of 9 people that filing names.
On the filing as: Executive Officer.
Gabi Tarcic is named as Vice President Product on the Form D that Evogene Ltd. filed with the SEC on 19 February 2026, one of 9 people that filing names.
On the filing as: Executive Officer.
Ilia Zhidkov is named as Vice President Computational Platform on the Form D that Evogene Ltd. filed with the SEC on 19 February 2026, one of 9 people that filing names.
On the filing as: Director.
Nir Nimrodi is named as Chairperson of the Board on the Form D that Evogene Ltd. filed with the SEC on 19 February 2026, one of 9 people that filing names.
Sarit Firon is named as Director on the Form D that Evogene Ltd. filed with the SEC on 19 February 2026, one of 9 people that filing names.
Dan Falk is named as Director on the Form D that Evogene Ltd. filed with the SEC on 19 February 2026, one of 9 people that filing names.
Adrian Percy is named as Director on the Form D that Evogene Ltd. filed with the SEC on 19 February 2026, one of 9 people that filing names.
Leon Recanati is named as Director on the Form D that Evogene Ltd. filed with the SEC on 19 February 2026, one of 9 people that filing names.
9 people named on the filing — 4 holding an executive role and 5 as directors only.
Named as of the 2026-02-19 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Evogene Ltd.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Evogene Ltd.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Evogene Ltd. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Evogene Ltd.You get an alert in MentionFox the next time this company shows up.
If you're behind Evogene Ltd.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Evogene Ltd.. With no account yet, you sign up free and land on the result.
https://mentionfox.com/funding/evogene-ltd-form-d-26000001